These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

332 related items for PubMed ID: 22429723

  • 1. In vitro activities of amphotericin B and AmBisome against Aspergillus isolates recovered from Italian patients treated for haematological malignancies.
    Colozza C, Posteraro B, Santilli S, De Carolis E, Sanguinetti M, Girmenia C.
    Int J Antimicrob Agents; 2012 May; 39(5):440-3. PubMed ID: 22429723
    [Abstract] [Full Text] [Related]

  • 2. Comparison of the Sensititre YeastOne colorimetric antifungal panel and Etest with the NCCLS M38-A method to determine the activity of amphotericin B and itraconazole against clinical isolates of Aspergillus spp.
    Martín-Mazuelos E, Pemán J, Valverde A, Chaves M, Serrano MC, Cantón E.
    J Antimicrob Chemother; 2003 Sep; 52(3):365-70. PubMed ID: 12917236
    [Abstract] [Full Text] [Related]

  • 3. Effects of amphotericin B on Aspergillus flavus clinical isolates with variable susceptibilities to the polyene in an experimental model of systemic aspergillosis.
    Barchiesi F, Spreghini E, Sanguinetti M, Giannini D, Manso E, Castelli P, Girmenia C.
    J Antimicrob Chemother; 2013 Nov; 68(11):2587-91. PubMed ID: 23794598
    [Abstract] [Full Text] [Related]

  • 4. Molecular identification and amphotericin B susceptibility testing of clinical isolates of Aspergillus from 11 hospitals in Korea.
    Heo MS, Shin JH, Choi MJ, Park YJ, Lee HS, Koo SH, Lee WG, Kim SH, Shin MG, Suh SP, Ryang DW.
    Ann Lab Med; 2015 Nov; 35(6):602-10. PubMed ID: 26354348
    [Abstract] [Full Text] [Related]

  • 5. Increased frequency of non-fumigatus Aspergillus species in amphotericin B- or triazole-pre-exposed cancer patients with positive cultures for aspergilli.
    Lionakis MS, Lewis RE, Torres HA, Albert ND, Raad II, Kontoyiannis DP.
    Diagn Microbiol Infect Dis; 2005 May; 52(1):15-20. PubMed ID: 15878437
    [Abstract] [Full Text] [Related]

  • 6. Amphotericin B in vitro resistance is associated with fatal Aspergillus flavus infection.
    Hadrich I, Makni F, Neji S, Cheikhrouhou F, Bellaaj H, Elloumi M, Ayadi A, Ranque S.
    Med Mycol; 2012 Nov; 50(8):829-34. PubMed ID: 22587728
    [Abstract] [Full Text] [Related]

  • 7. Intrinsic in vitro susceptibility of primary clinical isolates of Aspergillus fumigatus, Aspergillus terreus, Aspergillus nidulans, Candida albicans and Candida lusitaniae against amphotericin B.
    Singh J, Rimek D, Kappe R.
    Mycoses; 2006 Mar; 49(2):96-103. PubMed ID: 16466441
    [Abstract] [Full Text] [Related]

  • 8. In vitro susceptibilities of Aspergillus spp. causing otomycosis to amphotericin B, voriconazole and itraconazole.
    Kaya AD, Kiraz N.
    Mycoses; 2007 Nov; 50(6):447-50. PubMed ID: 17944704
    [Abstract] [Full Text] [Related]

  • 9. Treatment failure in invasive aspergillosis: susceptibility of deep tissue isolates following treatment with amphotericin B.
    Paterson PJ, Seaton S, Prentice HG, Kibbler CC.
    J Antimicrob Chemother; 2003 Nov; 52(5):873-6. PubMed ID: 14519673
    [Abstract] [Full Text] [Related]

  • 10. Characterization of clinical strains of Aspergillus terreus complex: molecular identification and antifungal susceptibility to azoles and amphotericin B.
    Escribano P, Peláez T, Recio S, Bouza E, Guinea J.
    Clin Microbiol Infect; 2012 Feb; 18(2):E24-6. PubMed ID: 22128886
    [Abstract] [Full Text] [Related]

  • 11. In vitro susceptibility testing of Candida and Aspergillus spp. to voriconazole and other antifungal agents using Etest: results of a French multicentre study.
    Mallié M, Bastide JM, Blancard A, Bonnin A, Bretagne S, Cambon M, Chandenier J, Chauveau V, Couprie B, Datry A, Feuilhade M, Grillot R, Guiguen C, Lavarde V, Letscher V, Linas MD, Michel A, Morin O, Paugam A, Piens MA, Raberin H, Tissot E, Toubas D, Wade A.
    Int J Antimicrob Agents; 2005 Apr; 25(4):321-8. PubMed ID: 15784312
    [Abstract] [Full Text] [Related]

  • 12. Comparative in vitro activities of posaconazole, voriconazole, itraconazole, and amphotericin B against Aspergillus and Rhizopus, and synergy testing for Rhizopus.
    Arikan S, Sancak B, Alp S, Hascelik G, McNicholas P.
    Med Mycol; 2008 Sep; 46(6):567-73. PubMed ID: 19180726
    [Abstract] [Full Text] [Related]

  • 13. Survey of amphotericin B susceptibility of Candida clinical isolates determined by Etest.
    Chiu YS, Chang SC, Hsueh PR, Wang JL, Sun HY, Chen YC.
    J Microbiol Immunol Infect; 2006 Aug; 39(4):335-41. PubMed ID: 16926981
    [Abstract] [Full Text] [Related]

  • 14. Antifungal susceptibility of the aspergillus species by Etest and CLSI reference methods.
    Badiee P, Alborzi A, Moeini M, Haddadi P, Farshad S, Japoni A, Ziyaeyan M.
    Arch Iran Med; 2012 Jul; 15(7):429-32. PubMed ID: 22724880
    [Abstract] [Full Text] [Related]

  • 15. [In vitro amphotericin B susceptibility of korean bloodstream yeast isolates assessed by the CLSI broth microdilution method, Etest, and Minimum fungicidal concentration test].
    Park JY, Shin JH, Uh Y, Kim EC, Kee SJ, Kim SH, Shin MG, Suh SP, Ryang DW.
    Korean J Lab Med; 2008 Oct; 28(5):346-52. PubMed ID: 18971615
    [Abstract] [Full Text] [Related]

  • 16. Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B.
    Walsh TJ, Petraitis V, Petraitiene R, Field-Ridley A, Sutton D, Ghannoum M, Sein T, Schaufele R, Peter J, Bacher J, Casler H, Armstrong D, Espinel-Ingroff A, Rinaldi MG, Lyman CA.
    J Infect Dis; 2003 Jul 15; 188(2):305-19. PubMed ID: 12854088
    [Abstract] [Full Text] [Related]

  • 17. In vitro susceptibility of Candida species to five antifungal agents in a German university hospital assessed by the reference broth microdilution method and Etest.
    Fleck R, Dietz A, Hof H.
    J Antimicrob Chemother; 2007 Apr 15; 59(4):767-71. PubMed ID: 17293369
    [Abstract] [Full Text] [Related]

  • 18. Water-soluble amphotericin B-polyvinylpyrrolidone complexes with maintained antifungal activity against Candida spp. and Aspergillus spp. and reduced haemolytic and cytotoxic effects.
    Charvalos E, Tzatzarakis MN, Van Bambeke F, Tulkens PM, Tsatsakis AM, Tzanakakis GN, Mingeot-Leclercq MP.
    J Antimicrob Chemother; 2006 Feb 15; 57(2):236-44. PubMed ID: 16361329
    [Abstract] [Full Text] [Related]

  • 19. Multicenter Study of Method-Dependent Epidemiological Cutoff Values for Detection of Resistance in Candida spp. and Aspergillus spp. to Amphotericin B and Echinocandins for the Etest Agar Diffusion Method.
    Espinel-Ingroff A, Arendrup M, Cantón E, Cordoba S, Dannaoui E, García-Rodríguez J, Gonzalez GM, Govender NP, Martin-Mazuelos E, Lackner M, Lass-Flörl C, Linares Sicilia MJ, Rodriguez-Iglesias MA, Pelaez T, Shields RK, Garcia-Effron G, Guinea J, Sanguinetti M, Turnidge J.
    Antimicrob Agents Chemother; 2017 Jan 15; 61(1):. PubMed ID: 27799206
    [Abstract] [Full Text] [Related]

  • 20. Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003.
    Hsueh PR, Lau YJ, Chuang YC, Wan JH, Huang WK, Shyr JM, Yan JJ, Yu KW, Wu JJ, Ko WC, Yang YC, Liu YC, Teng LJ, Liu CY, Luh KT.
    Antimicrob Agents Chemother; 2005 Feb 15; 49(2):512-7. PubMed ID: 15673726
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.